Bacillus subtilis Modulated the Expression of Osteogenic Markers in a Human Osteoblast Cell Line

Cells. 2023 Jan 19;12(3):364. doi: 10.3390/cells12030364.

Abstract

Several in vivo trials have previously demonstrated the beneficial effects of the administration of various probiotic forms on bone health. In this study, we explored the potency of two probiotics, Bacillus subtilis and Lactococcus lactis, alone or in combination with vitamin D (VD), to modulate the transcription of genes involved in the ossification process in a human osteoblast cell line. Genes that mark the "osteoblast proliferation phase", such as RUNX2, TGFB1, and ALPL, "extracellular matrix (ECM) maturation", such as SPP1 and SPARC, as well as "ECM mineralization", such as BGN, BGLAP, and DCN, were all highly expressed in osteoblasts treated with B. subtilis extract. The observed increase in the transcription of the ALPL mRNA was further in agreement with its protein levels as observed by Western blot and immunofluorescence. Therefore, this higher transcription and translation of alkaline phosphatase in osteoblasts treated with the B. subtilis extract, indicated its substantial osteogenic impact on human osteoblasts. Although both the probiotic extracts showed no osteogenic synergy with VD, treatment with B. subtilis alone could increase the ECM mineralization, outperforming the effects of L. lactis and even VD. Furthermore, these results supported the validity of employing probiotic extracts rather than live cells to investigate the effects of probiotics in the in vitro systems.

Keywords: alkaline phosphatase; hFOB 1.19 cells; mineralization; ossification genes; osteoblasts; probiotics; vitamin D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacillus subtilis*
  • Cell Line
  • Extracellular Matrix / metabolism
  • Humans
  • Osteoblasts / metabolism
  • Osteogenesis*

Grants and funding

This work was supported by the EU MSCA-ITN project BioMedAqu which has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 766347.